Antineutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis following COVID-19 BBIBP-CorV vaccine: A case report

Q3 Medicine Clinical Infection in Practice Pub Date : 2023-12-13 DOI:10.1016/j.clinpr.2023.100337

Parisa Javadian , Negin Fadaei-Tirani , Zainab Amoosoltani-Forooshani , Vahid Reisi-Vanani , Mina Borran

{"title":"Antineutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis following COVID-19 BBIBP-CorV vaccine: A case report","authors":"Parisa Javadian , Negin Fadaei-Tirani , Zainab Amoosoltani-Forooshani , Vahid Reisi-Vanani , Mina Borran","doi":"10.1016/j.clinpr.2023.100337","DOIUrl":null,"url":null,"abstract":"<div><p>COVID-19 and its vaccination could initiate autoimmunity including ANCA-associated vasculitis that could mimic COVID-19 infection symptoms. This misdiagnosis could increase the morbidity of AAV. Herein a case of AAV post-BBIBP-CorV (Sinopharm) COVID-19 vaccine was reported. A 32-years-old woman was admitted with flu-like symptoms, flank pain, hemoptysis, hematuria, and oliguria following the second dose of BBIBP-CorV vaccination. Due to her severe clinical course, she needed ICU care while plasma exchange, renal replacement therapy, corticosteroid pulse, and tocilizumab were the primary therapies that improved her symptoms. After more evaluation, she was diagnosed with AAV, and conservative therapy was initiated. Her pulmonary condition and renal function were resolved gradually. Reports of post-COVID-19 vaccination raised the need for assessment of the immune response caused by these vaccines. Physicians also should be aware of the misdiagnosis of AAV and other infectious diseases.</p></div>","PeriodicalId":33837,"journal":{"name":"Clinical Infection in Practice","volume":"21 ","pages":"Article 100337"},"PeriodicalIF":0.0000,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590170223001206/pdfft?md5=494e344a021d2f09f42668e27b87b95e&pid=1-s2.0-S2590170223001206-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Infection in Practice","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590170223001206","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

COVID-19 and its vaccination could initiate autoimmunity including ANCA-associated vasculitis that could mimic COVID-19 infection symptoms. This misdiagnosis could increase the morbidity of AAV. Herein a case of AAV post-BBIBP-CorV (Sinopharm) COVID-19 vaccine was reported. A 32-years-old woman was admitted with flu-like symptoms, flank pain, hemoptysis, hematuria, and oliguria following the second dose of BBIBP-CorV vaccination. Due to her severe clinical course, she needed ICU care while plasma exchange, renal replacement therapy, corticosteroid pulse, and tocilizumab were the primary therapies that improved her symptoms. After more evaluation, she was diagnosed with AAV, and conservative therapy was initiated. Her pulmonary condition and renal function were resolved gradually. Reports of post-COVID-19 vaccination raised the need for assessment of the immune response caused by these vaccines. Physicians also should be aware of the misdiagnosis of AAV and other infectious diseases.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

接种 COVID-19 BBIBP-CorV 疫苗后出现抗中性粒细胞胞浆抗体 (ANCA) 相关性血管炎：病例报告

COVID-19 及其疫苗接种可能会引发自身免疫，包括 ANCA 相关性血管炎，从而模仿 COVID-19 感染症状。这种误诊可能会增加 AAV 的发病率。本文报告了一例接种BBIBP-CorV（国药集团）COVID-19疫苗后感染AAV的病例。一名 32 岁女性在接种第二剂 BBIBP-CorV 疫苗后因流感样症状、侧腹疼痛、咯血、血尿和少尿入院。由于临床症状严重，她需要接受重症监护，而血浆置换、肾脏替代疗法、皮质类固醇脉冲和托珠单抗是改善其症状的主要疗法。经过进一步评估，她被确诊为 AAV，并开始接受保守治疗。她的肺部状况和肾功能逐渐恢复。有关 COVID-19 疫苗接种后的报告表明，有必要对这些疫苗引起的免疫反应进行评估。医生还应该注意对 AAV 和其他传染病的误诊。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊